It is an urgent need for developing biosensing platforms through point-of-care carbon dot-based biosensors for inexpensive, simple, rapid and reliable detection of several kinds of diseases in both medicine and industry. In our research, we aim to develop bacterial probes or cancer detection platforms which are activable in specific disease conditions for both identification via colorimetric assay or electrochemical behavior and simultaneously perform killing activity via theranostic agents.